Company news

Eupraxia Pharmaceuticals, Inc. (TSX:EPRX) news

Every Eupraxia Pharmaceuticals, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.

Eupraxia Pharmaceuticals, Inc. (TSX:EPRX) news

Press releases & updates

Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Pai...

Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results&#xA0;

Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth

Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization

Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders

Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results

Eupraxia Pharmaceuticals' First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis ...

Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease W...

Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer

Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting

Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/...

Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences

Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinoph...

Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results

Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option

Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option

Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants

Eupraxia Pharmaceuticals Announces Proposed Public Offering

Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Nea...

Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Nea...

Specific Biologics Welcomes Accomplished Biotechnology Leader Dr. Richard Glickman to its Board of Directors

Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating...

Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results

Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and P...

Peterson Capital Hosts Canada Growth Conference in Ireland

Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering&#xA0;Including Full Exercise of Underwriter Option

Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option

Eupraxia Pharmaceuticals Announces Pricing of US$70 Million Public Offering of Common Shares

Eupraxia Pharmaceuticals Announces Proposed Public Offering of Common Shares

First Set of 1-Year Clinical Results from RESOLVE Trial in Eosinophilic Esophagitis (EoE), Durable and Sustained Symptom & Tissue Respons...

Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences

Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders

"Bear-Pit Session" Highlights Peterson Capital's Canada Growth Conference in Montreal

Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic...

Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results

Eupraxia Pharmaceuticals Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Month...

Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May

Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results

Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Announces CFO Succession

Eupraxia's DiffuSphere(TM) Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six...

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Diso...

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic...

Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results

Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million

Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024

Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results

Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option